A Phase 2 in Patients With Mixed Dyslipidemia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Subcutaneously Administered BW-00112 in Patients with Mixed Dyslipidemia
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
145
BW-00112 or volume-matched placebo on Day 1 and Day 90
Alliance for Multispecialty Research, LLC
Daphne, Alabama, United States
Alliance for Multispecialty Research, LLC
Mobile, Alabama, United States
Percent change in fasting TG
Percent change in fasting TG from baseline to Day 180
Time frame: From baseline to Day 180
Percent change in fasting TG
Percent change in fasting TG from baseline to Day 15, 30, 60, 90, 135, 225, and 270
Time frame: From baseline to Day 15, 30, 60, 90, 135, 225, and 270
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Excel Medical Clinical Trials, LLC, dba Flourish Research
Boca Raton, Florida, United States
East Coast Institute for Research, LLC
Jacksonville, Florida, United States
Clinical Site Partners Leesburg, LLC dba Flourish Research
Leesburg, Florida, United States
Suncoast Research Group, LLC DBA Flourish Research
Miami, Florida, United States
Clinical Site Partners, LLC DBA Flourish Research
Miami, Florida, United States
East Coast Institute for Research LLC
Canton, Georgia, United States
Alliance for Multispecialty Research, LLC
Oak Brook, Illinois, United States
Alliance for Multispecialty Research, LLC
Park Ridge, Illinois, United States
...and 4 more locations